On May 4, 2020, the U.S. Trade Representative (“USTR”) announced that 146 items will be excluded from the Section 301 trade remedies imposed on Chinese-origin products. The newly announced exclusions all relate to items on China 301 List 3 (which is part of the $200 billion trade action) which, unless excluded, are currently subject to […]
outbreak
USTR SOLICITING COMMENTS ON THE REMOVAL OF CHINA SEC. 301 DUTIES FROM ADDITIONAL MEDICAL-CARE PRODUCTS
In a March 23, 2020 notice, the Office of the United States Trade Representative (“USTR”) has solicited comments identifying additional medical-care items that should be excluded from China Section 301 tariffs in light of the ongoing COVID-19 outbreak. The comment period will remain open at least until June 25, 2020 (subject to potential extensions as […]